Trastuzumab biosimilar, recombinant humanized IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2) that has been shown to inhibit the proliferation of HER2 overexpressing cancer . Indications: HER2 positive breast cancer (early and metastatic forms), metastatic adenocarcinoma of the stomach or gastro-esogeal junction with HER2 overexpression. Currently >20 000 patients treated, >283 000 vials sold, marketed in 7 countries
Signup today to claim your Discount. Get Started before it's too late!
